0000885590-15-000025.txt : 20150417 0000885590-15-000025.hdr.sgml : 20150417 20150417172817 ACCESSION NUMBER: 0000885590-15-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150415 FILED AS OF DATE: 20150417 DATE AS OF CHANGE: 20150417 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mirovsky Pavel CENTRAL INDEX KEY: 0001577638 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 15779090 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST CITY: LAVAL STATE: A8 ZIP: H7L 4A8 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2015-04-15 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001577638 Mirovsky Pavel 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8 QUEBEC, CANADA 0 1 0 0 President, EMENA Common Stock, no par value 2015-04-15 4 M 0 24175 0 A 34175 D Restricted Share Units 2015-04-15 4 M 0 24175 0 D Common Stock 48350 24175 D This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $108.97 starting on January 9, 2014 and the average stock price for the 20 trading days starting on each measurement dates: 25% on October 9, 2016, 50% on January 9, 2017 and 25% on April 9, 2017. Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value. Represents the maximum number of Common Shares that may be issued under the RSU award. by: Nicholas Zanoni for Pavel Mirovsky 2015-04-17